REGN241227C770000
- 0.13
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,186
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Jim Cramer Says He Supports Healthcare Stocks for Their Long-term Value
Wall Street Today: Market Barely Climbs, Wholesale Inflation Grows Less Than Feared
Could The Market Be Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Its Attractive Financial Prospects?
Live Stock News: Tuesday Market Climbs and TikTok Sale Might be Incoming
Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,185
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $950
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,120
Regeneron Pharma Price Target Cut to $795.00/Share From $895.00 by Citigroup
Regeneron Pharma Is Maintained at Neutral by Citigroup
Regeneron Pharmaceuticals Analyst Ratings
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $565 to $1,152
Regeneron (REGN) Gets a Buy From Bernstein
Wall Street Today: Market Turns Around, Let's See if it Lasts
Regeneron Pharmaceuticals To Present At J.P. Morgan Healthcare Conference; Webcast At 5:15 PM ET
Express News | Live On CNBC, Rob Sechan Announces Sold Regeneron
Express News | Regeneron Pharmaceuticals Inc : Jefferies Cuts Target Price to $1,120 From $1,200
Live Stock News: Monday Market Falling, 'Too Big to Fail' Earnings to Start Q1 Report Season
Citigroup Cuts Regeneron Pharmaceuticals' Price Target to $795 From $895